What is XAIR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XAIR?

P/E (TTM) is n/a and 52-week range is $2.05 to $55.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XAIR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XAIR?

The company profile lists revenue (TTM) near $8M, net income (TTM) near $-3.34B, EPS (TTM) near $-68.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Beyond Air Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Garden City, New York, US, 720K shares outstanding, ISIN US08862L2025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Beyond Air Inc

$XAIR

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$2.23

+0.91%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.

Employees

Website

www.beyondair.net/

IPO

2019-05-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)